SCHEMBL1343845

SCHEMBL1343845

Oc1ccccc1-c1cccc2ccsc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.43
ALDH1A1 P00352 3/20 0.39
HPGD P15428 3/20 0.39
HSD17B10 Q99714 2/20 0.39
CYP1A2 P05177 1/20 0.39
BCL2L1 Q07817 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
HTR2B P41595 2/20 0.38
CASP3 P42574 2/20 0.38
SENP8 Q96LD8 2/20 0.38
SENP7 Q9BQF6 2/20 0.38
SENP6 Q9GZR1 2/20 0.38
RAB9A P51151 1/20 0.38
MAOA P21397 2/20 0.36
ATR Q13535 1/20 0.36
CYP19A1 P11511 1/20 0.36
MAPT P10636 3/20 0.36
TP53 P04637 1/20 0.36
HDAC4 P56524 1/20 0.36
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL911242 0.81 CYP2A6 (0.50) CYP2A6ALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL1345599 0.80 NPC1 (0.41) CYP2A6CYP1A2SMN1; SMN2HTR2BMAPT
SCHEMBL28846883 0.78 RORC (0.44) CYP2A6ALDH1A1HSD17B10ATRTSHR
SCHEMBL17124466 0.77 CYP2A6 (0.43) CYP2A6ALDH1A1CYP1A2SMN1; SMN2CASP3
SCHEMBL19756685 0.76 ATR (0.46) CYP2A6ALDH1A1HPGDHSD17B10BCL2L1
Naphthalene SCHEMBL10525551 0.73 ALDH1A1 (0.57) CYP2A6ALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL13319523 0.73 CYP2A6 (0.43) CYP2A6HSD17B10MAOAATRHDAC4
SCHEMBL23716942 0.72 CCNB2 (0.43) ALDH1A1HPGDHSD17B10BCL2L1SMN1; SMN2
SCHEMBL28574 0.71 ALDH1A1 (0.67) ALDH1A1HPGDHSD17B10BCL2L1SMN1; SMN2
SCHEMBL30442890 0.71 ALDH1A1 (0.67) ALDH1A1HPGDHSD17B10BCL2L1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063035-B2 Triazolyl aminopyrimidine compounds ELI LILLY AND COMPANY (US) 2011-11-22 US disclosed
US-20100087431-A1 TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS ELI LILLY AND COMPANY 2010-04-08 US disclosed
EP-2155734-A2 TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS ELI LILLY AND COMPANY (US) 2010-02-24 EP disclosed
WO-2008144223-A2 TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS ELI LILLY AND COMPANY (US) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087431-A1 TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS DPYD, TP53, TYMP CYP2A6 1744/4885ALDH1A1 578/4885HPGD 1801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.